Verseau
is a Massachusetts-based biotechnology company that discovers and repolarizes macrophages for the treatment of cancer... Read moreVerseau
is a Massachusetts-based biotechnology company that discovers and repolarizes macrophages for the treatment of cancer... Read more
News
Jan 04, 2022
MarketScreener
Verseau: Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody
Sep 07, 2021
Citybizlist
Verseau: Verseau Therapeutics Appoints Karen Tubridy as Chief Development Officer
Dec 14, 2020
BioSpace
Verseau Therapeutics: Sunshine Guojian Selects Verseau's VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration
Aug 04, 2020
Boston Citybizlist
Verseau Therapeutics: Applied BioMath Announces Collaboration with Verseau Therapeutics
Nov 20, 2019
BioPortfolio
Verseau Therapeutics: 3SBio and Verseau Choose First Candidate in Microphage Immunotherapy Partnership
Nov 18, 2019
BioPortfolio
Verseau Therapeutics: 3SBio Selects Verseau's PSGL1targeted Antibody VTX0811 as First Partnered Macrophage Checkpoint Modulator in ImmunoOncology Collaboration
Nov 18, 2019
Biospectrum Asia
Verseau Therapeutics: PSGL-1 immunotherapy to activate a anti-tumor inflammatory response
Oct 22, 2019
BioPortfolio
Verseau Therapeutics: Verseau Raises $50 Million for Macrophage Immunotherapies; 3SBio Has China Rights
Oct 22, 2019
DealStreetAsia
Verseau Therapeutics: China's 3SBio, Highlight Capital, Yonghua back $50m Verseau Therapeutics round
Oct 21, 2019
VC News Daily
Verseau Therapeutics: Verseau Launches with $50M Financing
Verseau Competitors
1
2
3
4
5
6
7
8